Publications by authors named "Micaela Forshaw"
Article Synopsis
- Intranasal formulations, like zavegepant, offer an alternative treatment for migraine sufferers who can't tolerate oral medications due to side effects like nausea.
- This phase 3 trial involved 1978 adults with moderate to severe migraines, randomly assigning them to receive zavegepant nasal spray or a placebo and assessing outcomes like pain relief and bothersome symptoms after 2 hours.
- The study, conducted at 90 medical centers in the USA, aimed to evaluate the effectiveness, safety, and tolerability of zavegepant compared to placebo for acute migraine treatment.
Article Synopsis
- The study evaluated the effectiveness and safety of zavegepant nasal spray for treating migraines, focusing on its ability to provide quick pain relief and reduce bothersome symptoms.
- In a Phase 2/3 clinical trial involving 1,588 participants, the 10 mg and 20 mg doses of zavegepant significantly outperformed the placebo in achieving pain freedom and alleviating bothersome symptoms two hours after administration.
- Common side effects included dysgeusia (altered taste), occurring more frequently with zavegepant compared to the placebo, although the lower 5 mg dose did not show significant results.
Background: Rimegepant, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the acute treatment of migraine using a standard tablet formulation. The objective of this trial was to compare the efficacy, safety, and tolerability of a novel orally disintegrating tablet formulation of rimegepant at 75 mg with placebo in the acute treatment of migraine.
Methods: In this double-blind, randomised, placebo-controlled, multicentre phase 3 trial, adults aged 18 years or older with history of migraine of at least 1 year were recruited to 69 study centres in the USA.